BCYC Logo

Bicycle Therapeutics plc (BCYC) 

NASDAQ
Market Cap
$1.63B
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
461 of 776
Rank in Industry
242 of 433

Largest Insider Buys in Sector

BCYC Stock Price History Chart

BCYC Stock Performance

About Bicycle Therapeutics plc

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. The company's oncology product candidates also comprise BT5528, a BTC that is in a Phase I/II clinical trial targeting EphA2; and BT8009, which is in Phase I/II clinical trial targeting Nectin-4. In addition, …

Insider Activity of Bicycle Therapeutics plc

Over the last 12 months, insiders at Bicycle Therapeutics plc have bought $0 and sold $807,503 worth of Bicycle Therapeutics plc stock.

On average, over the past 5 years, insiders at Bicycle Therapeutics plc have bought $0 and sold $6.47M worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 628,572 shares for transaction amount of $8.8M was made by Cambridge Innovation Capital (Jersey) Ltd (10 percent owner) on 2019‑05‑29.

List of Insider Buy and Sell Transactions, Bicycle Therapeutics plc

2024-10-03SaleCHIEF EXECUTIVE OFFICER
3,212
0.0044%
$22.26$71,499+10.72%
2024-10-03SaleCHIEF TECHNOLOGY OFFICER
972
0.0013%
$22.26$21,637+10.72%
2024-10-03SaleCHIEF OPERATING OFFICER
972
0.0013%
$22.26$21,637+10.72%
2024-10-03SaleCHIEF BUSINESS OFFICER
972
0.0013%
$22.26$21,637+10.72%
2024-10-03SaleCHIEF ACCOUNTING OFFICER
153
0.0002%
$22.26$3,406+10.72%
2024-10-03SaleCHIEF PROD & SUPPLY CHAIN OFF
247
0.0003%
$22.26$5,498+10.72%
2024-07-03SaleCHIEF EXECUTIVE OFFICER
3,194
0.0073%
$19.64$62,7300.00%
2024-07-03SaleCHIEF TECHNOLOGY OFFICER
967
0.0022%
$19.64$18,9920.00%
2024-07-03SaleCHIEF OPERATING OFFICER
967
0.0022%
$19.64$18,9920.00%
2024-07-03SaleCHIEF SCIENTIFIC OFFICER
779
0.0018%
$19.64$15,3000.00%
2024-07-03SaleCHIEF BUSINESS OFFICER
967
0.0022%
$19.64$18,9920.00%
2024-07-03SaleCHIEF ACCOUNTING OFFICER
148
0.0003%
$19.64$2,9070.00%
2024-07-03SaleCHIEF PROD & SUPPLY CHAIN OFF
246
0.0006%
$19.64$4,8310.00%
2024-04-11SaleCHIEF PROD & SUPPLY CHAIN OFF
257
0.0006%
$22.49$5,780+2.47%
2024-04-03SaleCHIEF EXECUTIVE OFFICER
3,158
0.0076%
$23.81$75,192-1.22%
2024-04-03SaleCHIEF TECHNOLOGY OFFICER
955
0.0023%
$23.81$22,739-1.22%
2024-04-03SaleCHIEF OPERATING OFFICER
955
0.0023%
$23.81$22,739-1.22%
2024-04-03SaleCHIEF SCIENTIFIC OFFICER
790
0.0019%
$23.81$18,810-1.22%
2024-04-03SaleCHIEF BUSINESS OFFICER
955
0.0023%
$23.81$22,739-1.22%
2024-04-03SaleCHIEF ACCOUNTING OFFICER
152
0.0004%
$23.81$3,619-1.22%

Insider Historical Profitability

<0.0001%
TYBOURNE CAPITAL MANAGEMENT (HK) LTD10 percent owner
1957961
2.837%
$23.5810<0.0001%
HARLAND DEBORAHdirector
1915275
2.7751%
$23.5810<0.0001%
GLAXOSMITHKLINE PLC10 percent owner
1910531
2.7682%
$23.5812<0.0001%
SVLSF V, LLC10 percent owner
1875637
2.7177%
$23.5810<0.0001%
Novartis Bioventures Ltd10 percent owner
1769641
2.5641%
$23.5810<0.0001%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Baker Bros Advisors LP$123.08M9.944.94M+176.07%+$78.5M0.88
Deep Track Capital Lp$86.91M7.023.49M0%+$00.4
Paradigm BioCapital Advisors LP$80.84M6.533.25M-12.41%-$11.46M2.93
Armistice Capital Llc$41.63M3.361.67M+8.85%+$3.39M0.13
Tybourne Capital Management HK Ltd$38.47M3.111.55M-6.38%-$2.62M6.58
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.